- Title: Trust Beyond - Predictive Value of ultrasonographic parameters for therapy response in Crohn’s disease and ulcerative colitis patients
- Study drug: New-onset immunomodulator therapy; biologic or JAK-inhibitor therapy (first-, second-, or third-line)
- Sponsor: AbbVie Deutschland GmbH & Co. KG
- Participating centers and contact: Kantonsspital Liestal, PD Dr. med. Emanuel Burri (Emanuel.Burri@ksbl.ch)
- Target population: IBD patients with moderate to severe disease activity
- Primary outcome:
- Inclusion criteria:
- Exclusion criteria:
- More information: X